RxDoctor Payments Data

William Whitmire, MD

Ophthalmology · Soddy Daisy, TNNPI 1932492303

Payments from drug & device makers

$662in general payments, 2019–2025

Across 33 payments — averaging $20.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$231
  • Bausch & Lomb Americas Inc.$223
  • Alcon$113
  • Dompe US, Inc.$40
  • Pfizer$22
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$20
  • plus $13 from 1 others

What the payments were for

  • Food & beverage$64497%
  • Education$183%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$662 in reported general payments places this provider in the 30th percentile of 323 ophthalmology providers in Tennessee.

See all ophthalmology providers in Tennessee

Medicare billing

Part B allowed, 2024
$259,575
Medicare patients
1,122
Services billed
3,265

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost231$106,764
RestasisCyclosporine72$64,905
RhopressaNetarsudil Mesylate127$54,568
XiidraLifitegrast44$39,194
RocklatanNetarsudil Mesylat/Latanoprost67$31,450
VyzultaLatanoprostene Bunod53$19,304
Travoprost96$14,141
CombiganBrimonidine Tartrate/Timolol42$13,350
Bimatoprost132$11,785
Latanoprost791$8,495
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat400$7,979
Loteprednol Etabonate46$5,936
SimbrinzaBrinzolamide/Brimonidine Tart24$5,469
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol19$4,855
Prednisolone Acetate120$4,097

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan, Alphagan P$231$187,034356 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$223$58,49897 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$20$5,93646 claims
AlconSimbrinza$113$5,46924 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 323 ophthalmology providers in Tennessee.

Other ophthalmology in Soddy Daisy

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →